Dipexium Pharmaceuticals Inc  

(Public, NASDAQ:DPRX)   Watch this stock  
Find more results for Jack D. Duffy
14.16
+0.30 (2.16%)
Mar 27 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 13.51 - 14.74
52 week 8.00 - 15.14
Open 13.90
Vol / Avg. 16,047.00/23,539.00
Mkt cap 118.71M
P/E     -
Div/yield     -
EPS -1.73
Shares 8.56M
Beta     -
Inst. own 19%
Mar 24, 2015
Q4 2014 Dipexium Pharmaceuticals Inc Earnings Release
Mar 24, 2015
Q4 2014 Dipexium Pharmaceuticals Inc Earnings Call
Feb 9, 2015
Dipexium Pharmaceuticals Inc at Biotechnology Industry Organization CEO & Investor Conference
Jan 13, 2015
Dipexium Pharmaceuticals Inc at EBD Biotech Showcase
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '14) 2014
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -45.85% -86.95%
Return on average equity -47.99% -93.16%
Employees 5 -
CDP Score - -

Address

Suite 1905, 61 Broadway
NEW YORK, NY 10006
United States - Map
+1-212-2692834 (Phone)
+1-845-8183588 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

DIPEXIUM PHARMACEUTICALS, INC., is a biopharmaceutical company. The Company is focused on the development and commercialization of Locilex. Locilex is a chemically synthesized, 22-amino acid peptide isolated from the skin of the African Clawed Frog. Its mechanism of action kills microbial targets through disruption of bacterial cell membrane permeability. Locilex is also considered a product candidate, to treat mild or moderate acute bacterial skin and skin structure infections in superficial wounds, including infected decubitus ulcers, infected burns, infected surgical wounds and nasal colonization of methicillin-resistant staphylococcus aureus (MRSA). Locilex is initially being targeted for the treatment of mild infections of diabetic foot ulcers (Mild DFI). As of September, 30, 2014, the Company had not generated any revenues.

Officers and directors

Robert J. DeLuccia Executive Chairman of the Board
Age: 69
Bio & Compensation  - Reuters
David P. Luci Esq. President, Chief Executive Officer, Secretary, Director
Age: 46
Bio & Compensation  - Reuters
Robert G. Shawah CPA. Chief Accounting Officer, Treasurer
Age: 48
Bio & Compensation  - Reuters
David Garrett Vice President, Finance and Corporate Development, IR Contact Officer
Age: 38
Bio & Compensation  - Reuters
Christopher J. Coughlin Independent Director
Age: 62
Bio & Compensation  - Reuters
Jack Hugh Dean Ph.D. Independent Director
Age: 73
Bio & Compensation  - Reuters
Michael E. Duffy Esq. Independent Director
Age: 44
Bio & Compensation  - Reuters
Thomas L. Harrison Independent Director
Age: 67
Bio & Compensation  - Reuters
William J. McSherry Jr., Esq. Independent Director
Age: 65
Bio & Compensation  - Reuters